Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside

H1 results showed 16% sales growth, a 44% net profit increase, and EBITDA margin expansion to 34.8%, driven by higher asset utilization and segment outperformance. Integrated Biologics, Advanced Synthesis, and Specialized Modalities each delivered double-digit growth. Management raised its 2026 CORE EBITDA margin outlook to 33–34% while maintaining 11–12% sales growth guidance. Our buy rating is confirmed.

Here at the Lab, we are back to comment on Lonza Group AG (LZAGY) (LZAGF), following the company's H1 release. In our last update, we continued to buy-rate Lonza's.